TBPH · Theravance Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.70M | - | $19.99M | $26.20M | $15.39M | - | $16.87M | $14.26M | $14.50M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.83M | - | $8.11M | $10.49M | $11.45M | - | $9.27M | $9.95M | $8.97M | - |
| SG&A | $17.72M | - | $18.33M | $18.43M | $18.37M | - | $16.88M | $17.06M | $16.74M | - |
| Total Operating Expenses | $27.18M | - | $26.45M | $28.92M | $29.82M | - | $27.70M | $29.96M | $25.71M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($9.48M) | - | ($6.46M) | ($2.73M) | ($14.43M) | - | ($10.84M) | ($15.71M) | ($11.21M) | - |
| Interest Expense | - | - | $573.0K | $663.0K | $629.0K | - | $630.0K | $568.0K | $629.0K | - |
| Income Tax | ($1.54M) | - | ($6.50M) | $18.37M | ($559.0K) | - | $2.65M | $1.31M | $1.26M | - |
| Net Income | ($4.93M) | - | $3.62M | $54.84M | ($13.58M) | - | ($12.70M) | ($16.53M) | ($11.66M) | - |
| EPS - Basic | ($0.10) | - | $0.07 | $1.09 | ($0.27) | - | ($0.26) | ($0.34) | ($0.24) | - |
| EPS - Diluted | ($0.10) | - | $0.07 | $1.08 | ($0.27) | - | ($0.26) | ($0.34) | ($0.24) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $288.10M | $167.81M | $174.77M | $281.93M | $110.61M | $37.80M | $23.38M | $46.34M | $53.84M | $39.55M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.10M | $2.57M | $2.21M | $1.68M | $2.41M | $2.24M | $1.45M | $1.67M | $1.69M | $1.52M |
| Current Assets | $417.63M | $418.46M | $354.70M | $366.29M | $150.26M | $161.07M | $116.48M | $119.31M | $124.29M | $133.54M |
| Total Assets | $472.31M | $485.57M | $415.46M | $426.04M | $343.58M | $354.16M | $356.11M | $362.03M | $371.31M | $382.00M |
| Current Liabilities | $31.77M | $38.30M | $37.41M | $54.63M | $31.50M | $32.09M | $23.43M | $22.95M | $21.66M | $24.77M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $290.59M | $296.72M | $232.68M | $224.85M | $165.98M | $175.54M | $185.65M | $193.69M | $204.87M | $213.00M |
| Retained Earnings | ($864.56M) | ($859.63M) | ($920.65M) | ($924.27M) | ($979.10M) | ($965.52M) | ($950.00M) | ($937.30M) | ($920.77M) | ($909.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $73.28M | - | - | - | $43.04M | - | - | - | ($1.02M) | - |
| Investing Cash Flow | $52.59M | - | - | - | $30.63M | - | - | - | $17.03M | - |
| Financing Cash Flow | ($5.58M) | - | - | - | ($854.0K) | - | - | - | ($1.72M) | - |
| CapEx | - | - | - | - | - | - | - | - | $91.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($1.11M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -53.6% | - | -32.3% | -10.4% | -93.8% | - | -64.2% | -110.2% | -77.3% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -27.9% | - | 18.1% | 209.3% | -88.2% | - | -75.3% | -115.9% | -80.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -7.7% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.10 | - |
| R&D / Revenue | 32.9% | - | 40.6% | 40.0% | 74.4% | - | 54.9% | 69.8% | 61.8% | - |
| SG&A / Revenue | 100.1% | - | 91.7% | 70.4% | 119.4% | - | 100.0% | 119.6% | 115.4% | - |
| Effective tax rate | - | - | - | 25.1% | - | - | - | - | - | - |
| Return on assets | -1.0% | - | 0.9% | 12.9% | -4.0% | - | -3.6% | -4.6% | -3.1% | - |
| Return on equity | -1.7% | - | 1.6% | 24.4% | -8.2% | - | -6.8% | -8.5% | -5.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 13.14 | 10.93 | 9.48 | 6.70 | 4.77 | 5.02 | 4.97 | 5.20 | 5.74 | 5.39 |
| Quick ratio | 13.14 | 10.93 | 9.48 | 6.70 | 4.77 | 5.02 | 4.97 | 5.20 | 5.74 | 5.39 |
| Cash ratio | 9.07 | 4.38 | 4.67 | 5.16 | 3.51 | 1.18 | 1.00 | 2.02 | 2.49 | 1.60 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -11.3x | -4.1x | -22.9x | - | -17.2x | -27.6x | -17.8x | - |
| Equity multiplier | 1.63 | 1.64 | 1.79 | 1.89 | 2.07 | 2.02 | 1.92 | 1.87 | 1.81 | 1.79 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.05 | 0.06 | 0.04 | - | 0.05 | 0.04 | 0.04 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 208.6x | 10.2x | - | - | - | - | - | - |
| P / B | 2.9x | - | 3.3x | 2.5x | 2.7x | - | 2.1x | 2.1x | 2.1x | - |
| P / S | 47.0x | - | 37.9x | 21.4x | 28.8x | - | 23.4x | 29.0x | 29.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 15.0% | - | 18.5% | 83.7% | 6.1% | - | 7.5% | 3.7% | 39.2% | - |
| Revenue CAGR (3y) | 19.3% | - | 17.1% | 33.3% | 5.3% | - | 8.5% | 3.4% | 0.6% | - |
| Revenue CAGR (5y) | 4.4% | - | 1.8% | 11.8% | -5.0% | - | 6.3% | -11.4% | 22.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 34.3% | - | 40.4% | 82.6% | -28.8% | - | -23.7% | 2.6% | 55.0% | - |
| Net income growth (YoY) | 63.7% | - | - | - | -16.4% | - | -41.9% | -5.7% | 47.2% | - |
| EPS growth (YoY) | 63.0% | - | - | - | -12.5% | - | -52.9% | -21.4% | 31.4% | - |
| EPS CAGR (3y) | - | - | -82.1% | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 90.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 75.1% | 69.0% | 25.3% | 16.1% | -19.0% | -17.6% | -24.6% | -30.9% | -44.7% | -51.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$107.46M totalSingle Reportable Segment$107.46M · 100.0%
Product / service
$233.27M totalYupelri Monotherapy$93.31M · 40.0%
Collaborative Arrangement Revenue$74.96M · 32.1%
Licensing And Milestone$32.50M · 13.9%
Milestone$25.00M · 10.7%
License$7.50M · 3.2%
Geographic
$107.46M totalUS$74.96M · 69.8%
Europe$32.50M · 30.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Theravance Biopharma against the 5 most active filers in the same SIC group.